Research programme: adeno-associated virus based gene therapies - AGTC/Synpromics

Drug Profile

Research programme: adeno-associated virus based gene therapies - AGTC/Synpromics

Alternative Names: AAV-based gene therapies

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 10 Nov 2017 Applied Genetic Technologies Corporation receives patent allowance for method of adeno-associated virus based gene therapies manufacturing in USA, before November 2017
  • 09 Dec 2015 AGTC and Synpromics enter into a research collaboration for the development of synthetic promotors as gene therapy candidate
  • 09 Dec 2015 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top